*February 2025*
In this video, Stephen Liu, MD, of the Georgetown University School of Medicine and Georgetown’s Lombardi Comprehensive Cancer Center in Washington, DC, joined Lung Cancers Today to discuss the recent announcement that the phase 3 MARIPOSA trial met its final pre-specified secondary endpoint of overall survival (OS). The randomized study has been evaluating amivantamab-vmjw plus lazertinib with osimertinib as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R substitution mutations. Watch video here.
